Member Info for Timster

Why a drop today to the the 50s

Because that's the placing price, in the history of all placings the SP always drops to the placing price.

Gobble gobble

Phase 1a full data including 2 week study Q2 2024 (it'll be end of June) all these new twats will be gone and with any luck we'll be back up.

Potential phase 3, that was mentioned with the data too.

Potential so not definite

Dyou know what aka7000 does?

Eggy, is that you?

One thing's for sure they'll be no chance to sell tomorrow as it plummets and levels off around the placing price.

Sulphurous smell to it

LDA

The dose expansions are expected to be in several orphan indications including soft tissue sarcomas and the selection of these dose expansion indications will be informed by data from the ongoing two-weekly and three-weekly dose escalation studies.

Kong read the RNS . It says H2 for dose expansion. But then has this section:

AVA6000:

o Read out of two-weekly and three-weekly dose escalation study data in late Q2 2024;

o Presentation of Phase 1 three-weekly study clinical data at AACR 2024 in April 2024; and

o Establish recommended Phase 2 dose in Q3 2024, initiating the dose expansion phase in the US in H2 2024, followed by the Phase 2 study, subject to funding and FDA approval.

Don't forget Boris swore on the bible in the COVID enquiry.

It did burst into flames though.

Anyone know any different, is this a new stage as it would appear to be.

So the way I read it 2 week study has begun.

I think he is NY, MO start positive then.....

Agreed

Designed to take out Dox?

The dose expansions are expected to be in several orphan indications including soft tissue sarcomas and the selection of these dose expansion indications will be informed by data from the ongoing two-weekly and three-weekly dose escalation studies.

The dose expansions are expected to be in several orphan indications including soft tissue sarcomas and the selection of these dose expansion indications will be informed by data from the ongoing two-weekly and three-weekly dose escalation studies.

So it's new, testing against different cancer types

Like this you mean:

a 59-year-old male with the diagnosis of undifferentiated pleomorphic sarcoma, treated at 160 mg/m2 on a three-weekly dosing ("q3w"), resulted in a partial response with a duration of greater than 6 months and a tumour volume reduction of ~65%. treatment is ongoing, with high fap expression observed in the tumour tissue and a favourable pk profile with reduction in auc which permits dosing for 7 additional cycles (~21 weeks); and

· a 79-year-old female with the diagnosis of angiosarcoma of the spleen has been treated at 250 mg/m2 q3w, with minor response with visceral (hepatic) metastases resulting in a reduction of 14% at cycle 2 and ~22% at cycle 4, with a continued shrinkage of liver metastases at cycle 4 scan, with interval development of new bone metastases (mixed response).

Read the RNS it's pretty good (not the placing one)

Yeah the dose expansion does seem to be a new phase, sure jive turkey will know what it is?

They have done very well fair play. And the greedy fleckers are still desperately trying to drive the price lower that the inevitable 50p that it will be tomorrow.